Corton Capital Inc. Editas Medicine, Inc. Transaction History

Corton Capital Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$7.03 - $11.07 $39,747 - $62,589	-5,654 Reduced 26.31%	15,832 $117,000
Q4 2023 Feb 14, 2024	SELL	$6.25 - $11.11 $49,243 - $87,535	-7,879 Reduced 26.83%	21,486 $217,000
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $107,882 - $145,142	15,590 Added 113.18%	29,365 $229,000
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $87,609 - $157,999	13,775 New	13,775 $113,000
Q3 2022 Nov 14, 2022	SELL	$12.16 - $19.42 $43,593 - $69,620	-3,585 Reduced 24.69%	10,933 $134,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $28,980 - $61,936	2,901 Added 24.97%	14,518 $172,000
Q1 2022 May 16, 2022	BUY	$14.08 - $27.63 $163,567 - $320,977	11,617 New	11,617 $221,000

240

56.5M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $85.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.